Preoperative Bevacizumab for Vitreous Hemorrhage

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous hemorrhage.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Bevacizumab; Temazepam

Criteria

Inclusion Criteria:

• Diabetic retinopathy causing significant vitreous hemorrhage with visual acuity loss lasting more than three months in patients not previously treated and four months in those previously LASER treated.

Exclusion Criteria:

• Previous intra-ocular surgery other than cataract surgery

• Retinal detachment

• Use of anticoagulants drugs other than aspirin

• Vitreous hemorrhage clearance at week-3 study period

• History of previous thromboembolic events